Three Stocks That May Be Trading Below Their Estimated Value

In This Article:

In recent weeks, global markets have experienced a mix of optimism and caution, with U.S. indexes nearing record highs amid strong labor market data and positive sentiment in the housing sector. Meanwhile, geopolitical tensions and economic uncertainties in regions like Europe and Japan have kept investors vigilant as they navigate these complex conditions. In this environment, identifying stocks that may be trading below their estimated value can present unique opportunities for investors seeking to capitalize on potential growth while managing risk effectively.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Gaming Realms (AIM:GMR)

£0.3665

£0.73

49.6%

BMC Medical (SZSE:301367)

CN¥68.90

CN¥137.12

49.8%

Tongqinglou Catering (SHSE:605108)

CN¥21.87

CN¥43.43

49.6%

Winking Studios (Catalist:WKS)

SGD0.27

SGD0.54

49.6%

EnomotoLtd (TSE:6928)

¥1479.00

¥2934.35

49.6%

Equity Bancshares (NYSE:EQBK)

US$49.21

US$98.42

50%

Intermedical Care and Lab Hospital (SET:IMH)

THB4.94

THB9.86

49.9%

Atlas Arteria (ASX:ALX)

A$4.88

A$9.67

49.5%

Fine Foods & Pharmaceuticals N.T.M (BIT:FF)

€7.88

€15.63

49.6%

Chengdu Olymvax Biopharmaceuticals (SHSE:688319)

CN¥10.91

CN¥21.64

49.6%

Click here to see the full list of 923 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's review some notable picks from our screened stocks.

Planisware SAS

Overview: Planisware SAS is a business-to-business software-as-a-service provider operating in Europe, the Americas, the Asia-Pacific, and internationally, with a market cap of €1.68 billion.

Operations: The company generates revenue primarily from its Software & Programming segment, amounting to €170.48 million.

Estimated Discount To Fair Value: 19.6%

Planisware SAS is trading at €23.95, approximately 19.6% below its estimated fair value of €29.8, suggesting potential undervaluation based on cash flows. Despite a decrease in net income to €15.98 million for the half-year ending June 30, 2024, compared to the previous year, revenue increased to €86.63 million from €72.2 million. Revenue growth is forecasted at 15% annually, surpassing the French market's average growth rate of 5.6%.

ENXTPA:PLNW Discounted Cash Flow as at Nov 2024
ENXTPA:PLNW Discounted Cash Flow as at Nov 2024

Bonesupport Holding

Overview: Bonesupport Holding AB is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes globally, with a market cap of SEK24.36 billion.